Cara Therapeutic Stock Today

CARA Stock  USD 5.20  0.08  1.56%   

Performance

Insignificant

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
Cara Therapeutic is trading at 5.20 as of the 19th of March 2025, a 1.56 percent increase since the beginning of the trading day. The stock's open price was 5.12. Cara Therapeutic has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
31st of January 2014
Category
Healthcare
Classification
Health Care
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. The company has 4.57 M outstanding shares of which 66.37 K shares are currently shorted by private and institutional investors with about 3.62 trading days to cover. More on Cara Therapeutic

Moving against Cara Stock

  0.54VANI Vivani Medical Earnings Call This WeekPairCorr
  0.51VKTX Viking TherapeuticsPairCorr
  0.42VERA Vera TherapeuticsPairCorr
  0.42VRCA Verrica PharmaceuticalsPairCorr
  0.37DSGN Design TherapeuticsPairCorr
  0.34VINC Vincerx PharmaPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Cara Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentChristopher Posner
Thematic IdeaMarijuana (View all Themes)
Old Names[Cara Operations Limited, Carasent ASA]
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Marijuana, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.20.1628
Fairly Up
Very volatile
Total Current Liabilities3.8 MM
Notably Down
Slightly volatile
Non Current Liabilities Total46.7 M44.4 M
Sufficiently Up
Slightly volatile
Total Assets41.6 M43.8 M
Notably Down
Slightly volatile
Total Current Assets41.6 M43.8 M
Notably Down
Slightly volatile
Debt Levels
Cara Therapeutic can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cara Therapeutic's financial leverage. It provides some insight into what part of Cara Therapeutic's total assets is financed by creditors.
Liquidity
Cara Therapeutic currently holds 48.42 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Cara Therapeutic has a current ratio of 8.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cara Therapeutic's use of debt, we should always consider it together with its cash and equity.

Change In Cash

(14.99 Million)
Cara Therapeutic (CARA) is traded on NASDAQ Exchange in USA. It is located in 400 Atlantic Street, Stamford, CT, United States, 06901 and employs 10 people. Cara Therapeutic is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 23.42 M. Cara Therapeutic conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 4.57 M outstanding shares of which 66.37 K shares are currently shorted by private and institutional investors with about 3.62 trading days to cover. Cara Therapeutic currently holds about 157.51 M in cash with (60.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93.
Check Cara Therapeutic Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Cara Therapeutic is $23.42 Million. Cara Therapeutic shows 13.17 percent of its outstanding shares held by insiders and 24.52 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cara Ownership Details

Cara Stock Institutional Holders

InstituionRecorded OnShares
Rathbone Brothers Plc2024-09-30
20.2 K
Fmr Inc2024-12-31
19.4 K
State Street Corp2024-12-31
14.9 K
Bnp Paribas Arbitrage, Sa2024-12-31
13.4 K
Lpl Financial Corp2024-12-31
12.2 K
Ubs Group Ag2024-12-31
8.1 K
Citigroup Inc2024-12-31
1.9 K
Jpmorgan Chase & Co2024-12-31
1.4 K
Morgan Stanley - Brokerage Accounts2024-12-31
1.3 K
Vanguard Group Inc2024-12-31
168.1 K
Rockefeller Capital Management L.p.2024-12-31
155.7 K
View Cara Therapeutic Diagnostics

Cara Therapeutic Historical Income Statement

At present, Cara Therapeutic's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 78.6 M, whereas Depreciation And Amortization is forecasted to decline to about 182.4 K. View More Fundamentals

Cara Stock Against Markets

Cara Therapeutic Corporate Management

Joana GoncalvesChief Medical OfficerProfile
Joana MDChief OfficerProfile
Frdrique MenzaghiChief RDProfile
Scott TerrillionChief Compliance Officer, General Counsel, SecretaryProfile
Beth WeinbergVP QAProfile
Eric VandalSenior CommercialProfile
When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(15.53)
Revenue Per Share
1.564
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.41)
Return On Equity
(2.70)
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.